Elanders changes the date for the publication of the Quarterly Report January-September 2020 and invites to a Conference Call
Elanders’ Board of Directors has decided to change the publication date of the Quarterly Report January-September 2020 to Friday October 23 at 07:30 CET instead of Thursday October 22 as earlier announced. The publication of the Quarterly Report on October 23, 2020, will be followed by a conference call at 09:30 CET, hosted by President and CEO Magnus Nilsson and CFO Andréas Wikner.
We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference.
To join this event, please use the below Click to Join link 5-10 minutes prior to start time, where you will be asked to enter your phone number and registration details. Our Event Conferencing system will call you on the phone number you provide and place you into the event. Please note that the Click To Join link will be active 15 minutes prior to the event.
Use the Click to Join option above for the easiest way to join your conference or use one of the access numbers below:
Sweden: +46 (0)8 5033 6546
Germany: +49 (0)69 2222 10763
UK: +44 (0)330 336 9401
USA: +1 646-828-8195
Participant Passcode: 376733
09:20 Conference number is opened
09:30 Presentation of quarterly results
10:30 End of the conference
During the conference call a presentation will be held. To access the presentation, please use this link:
For further questions, please contact
Magnus Nilsson, President and CEO, telephone: +46 31 750 07 50
Andréas Wikner, CFO, telephone: +46 31 750 07 50
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
NetAlly Announces Simplified Wi-Fi Multi-Floor Planning and other Improvements in AirMagnet® Survey PRO1.12.2020 07:00:00 CET | Press release
Wireless network professionals will now be able to design Wi-Fi 6 networks for multi-floor environments quickly and easily. COLORADO SPRINGS, Colo., Dec. 01, 2020 (GLOBE NEWSWIRE) -- NetAlly continues to prove their commitment to support AirMagnet customers by releasing version 10.1 of their Survey PRO software. This new release introduces multiple installation workflow improvements and enhanced support for active surveys while using an Intel Wi-Fi 6 radio, but most importantly it also makes it easier to design Wi-Fi 6 networks in a multi-floor environment by adding the “Advisor Tool” to the AirMagnet Multi-Floor Planner. “This provides Wi-Fi network professionals using AirMagnet Survey PRO a fast, efficient way to design for multi-floor installations,” says Julio Petrovitch, NetAlly Product Manager. “The Advisor Tool allows you to specify multiple Wi-Fi 6 network requirements, and then automatically calculates the optimal placement of access points throughout an entire multi-floor bui
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 20201.12.2020 07:00:00 CET | Press release
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors, will give a presentation at the ISGE (International Society of Gynecological Endocrinology) 19th World Congress Virtual Edition, December 2-5, 2020. Dr Loumaye’s presentation will take place during the symposium available on demand on Friday December 4th from 08:00 am GMT and accessible for 4 months. The link to the Congress and sessions will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com Symposium: IVF AND PREGNANCY: Recent development in IVF Date: Friday December 4th Title: The use of a novel oxytocin receptor antagonist, nolasiban, prior to embryo transfer: does it help? About ObsEva ObsEva is a biopharmaceutical compa
Sinch AB (publ): Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management30.11.2020 23:58:07 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har, i enlighet med Bolagets tidigare pressmeddelande idag den 30 november 2020 och med stöd av årsstämmans bemyndigande från den 15 maj 2020, beslutat om en riktad nyemission om 3 187 736 nya aktier till en teckningskurs om 1 050 kronor per aktie (”Nyemissionen”), motsvarande
Sinch AB (publ): Sinch announces the completion of a directed new share issue of 3,187,736 shares, raising approx. SEK 3.3 billion, and larger shareholders’ sale of existing shares to a fund managed by SB Management30.11.2020 23:58:07 CET | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Press Release Stockholm, 30 November 2020 Sinch announces the completion of a directed new share issue of 3,187,736 shares, raising approx. SEK 3.3 billion, and larger shareholders’ sale of existing shares to a fund managed by SB Management Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (“Sinch” or the “Company”) has, in accordance with the Company’s press release earlier today on 30 November 2020 and based on the authorization granted by the annual general meeting on 15 May 2020, resolved on a directed issue of 3,187,736 new shares at a subscription price of SEK 1,050 per share (the “Share Issue”), corresponding to (i) a discount of a
Stop & Shop Local Unions Ratify Previously Announced Withdrawal Agreement on UFCW International Union - Industry Pension Fund; No Impact to Previously Issued Outlook30.11.2020 22:30:00 CET | Press release
Zaandam, the Netherlands, November 30, 2020 – Ahold Delhaize announces today that the UFCW Locals of its U.S. brand Stop & Shop have ratified the agreement to terminate participation in the United Food & Commercial Workers International Union – Industry Pension Fund (the “National Plan”). As previously announced, the agreement does not impact the 2020 financial outlook. Details of the financial impact were outlined in the original release on July 21st, 2020, and can be found here. This withdrawal improves the security of pension benefits for associates as well as reduces financial risk for the company and was determined, by the National Plan’s trustees, to be in the best interests of the National Plan’s participants and beneficiaries. Also as previously announced, Stop & Shop, together with Kroger and the UFCW Locals, are creating the UFCW International Union-Industry Variable Annuity Pension Plan for future benefits. This new plan is designed to protect the benefit accrual of particip
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial30.11.2020 22:01:00 CET | Press release
Placebo-adjusted improvement in forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeksCorrelation between FVC decline and pulmonary lobar volume change observed, as measured by functional respiratory imaging (FRI) GLPG1205 planned to progress to dose finding Phase 2b study Mechelen, Belgium; 30 November 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its investigational GPR84 antagonist GLPG1205 in Proof-of-Concept Phase 2 trial in idiopathic pulmonary fibrosis (IPF) patients. The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating a 100mg once-daily oral dose of GLPG1205. The study recruited and included a total of 68 IPF patients. Participants were administered drug candidate or placebo (2:1 randomization) for 26 weeks and could remain on their standard of care as background therapy, i.e. nintedanib, pirfenidone or neither. The primary objective of the trial was to assess the chang